Novel therapeutic strategies to counter Pseudomonas aeruginosa infections

References

• Stover CK, Pham XQ, Erwin AL et al. Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic pathogen. Nature406(6799), 959–964 (2000).
   PubMed Web of Science ®Google Scholar
• Carson LA, Favero MS, Bond WW, Petersen NJ. Factors affecting comparative resistance of naturally occurring and subcultured Pseudomonas aeruginosa to disinfectants. Appl. Microbiol.23(5), 863–869 (1972).
   PubMedGoogle Scholar
• Wong S, Street D, Delgado SI, Klontz KC. Recalls of foods and cosmetics due to microbial contamination reported to the U.S. Food and Drug Administration. J. Food Prot.63(8), 1113–1116 (2000).
   PubMed Web of Science ®Google Scholar
• Rahme LG, Stevens EJ, Wolfort SF, Shao J, Tompkins RG, Ausubel FM. Common virulence factors for bacterial pathogenicity in plants and animals. Science268(5219), 1899–1902 (1995).
   PubMed Web of Science ®Google Scholar
• Sarlangue J, Brissaud O, Labreze C. [Clinical features of Pseudomonas aeruginosa infections]. Arch. Pediatr.13(Suppl. 1), S13–S16 (2006).
   Google Scholar
• Franzetti F, Cernuschi M, Esposito R, Moroni M. Pseudomonas infections in patients with AIDS and AIDS-related complex. J. Intern. Med.231(4), 437–443 (1992).
   PubMed Web of Science ®Google Scholar
• Lode H, Raffenberg M, Erbes R, Geerdes-Fenge H, Mauch H. Nosocomial pneumonia: epidemiology, pathogenesis, diagnosis, treatment and prevention. Curr. Opin. Infect. Dis.13(4), 377–384 (2000).
   PubMed Web of Science ®Google Scholar
• Thomas P, Moore M, Bell E et al.Pseudomonas dermatitis associated with a swimming pool. JAMA253(8), 1156–1159 (1985).
   PubMed Web of Science ®Google Scholar
• Lyczak JB, Cannon CL, Pier GB. Establishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunist. Microbes Infect.2(9), 1051–1060 (2000).
   PubMed Web of Science ®Google Scholar
• Saltzstein D, Wachs B, Perroncel R et al. Complicated urinary tract infections treated with extended-release ciprofloxacin with emphasis on Pseudomonas aeruginosa. J. Chemother.19(6), 694–702 (2007).
   PubMed Web of Science ®Google Scholar
• Fleiszig SM, Evans DJ. The pathogenesis of bacterial keratitis: studies with Pseudomonas aeruginosa. Clin. Exp. Optom.85(5), 271–278 (2002).
   PubMedGoogle Scholar
• Hart CA, Winstanley C. Persistent and aggressive bacteria in the lungs of cystic fibrosis children. Br. Med. Bull.61, 81–96 (2002).
   PubMed Web of Science ®Google Scholar
• Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. Thorax65(Suppl. 1), i1–i58 (2010).
   Google Scholar
• Mesaros N, Nordmann P, Plesiat P et al.Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin. Microbiol. Infect.13(6), 560–578 (2007).
   PubMed Web of Science ®Google Scholar
• Zavascki AP, Carvalhaes CG, Picao RC, Gales AC. Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev. Anti Infect. Ther.8(1), 71–93 (2010).
   PubMed Web of Science ®Google Scholar
• Vinodkumar CS, Kalsurmath S, Neelagund YF. Utility of lytic bacteriophage in the treatment of multidrug-resistant Pseudomonas aeruginosa septicemia in mice. Indian J. Pathol. Microbiol.51(3), 360–366 (2008).
   PubMed Web of Science ®Google Scholar
• Spencker FB, Staber L, Lietz T, Schille R, Rodloff AC. Development of resistance in Pseudomonas aeruginosa obtained from patients with cystic fibrosis at different times. Clin. Microbiol. Infect.9(5), 370–379 (2003).
   PubMed Web of Science ®Google Scholar
• Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin. Infect. Dis.43(Suppl. 2), S49–S56 (2006).
   PubMed Web of Science ®Google Scholar
• Nichols WW, Dorrington SM, Slack MP, Walmsley HL. Inhibition of tobramycin diffusion by binding to alginate. Antimicrob. Agents Chemother.32(4), 518–523 (1988).
   PubMed Web of Science ®Google Scholar
• Pages JM, James CE, Winterhalter M. The porin and the permeating antibiotic: a selective diffusion barrier in Gram-negative bacteria. Nat. Rev. Microbiol.6(12), 893–903 (2008).
   PubMed Web of Science ®Google Scholar
• Lambert PA. Mechanisms of antibiotic resistance in Pseudomonas aeruginosa. J. R. Soc. Med.95(Suppl. 41), 22–26 (2002).
   PubMed Web of Science ®Google Scholar
• Piddock LJ. Multidrug-resistance efflux pumps – not just for resistance. Nat. Rev. Microbiol.4(8), 629–636 (2006).
   PubMed Web of Science ®Google Scholar
• Kohler T, Michea-Hamzehpour M, Henze U, Gotoh N, Curty LK, Pechere JC. Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa. Mol. Microbiol.23(2), 345–354 (1997).
   PubMed Web of Science ®Google Scholar
• Masterton RG, Turner PJ. Trends in antimicrobial susceptibility in UK centres: the MYSTIC Programme (1997–2002). Int. J. Antimicrob. Agents27(1), 69–72 (2006).
   PubMed Web of Science ®Google Scholar
• Bendig JW, Kyle PW, Giangrande PL, Samson DM, Azadian BS. Two neutropenic patients with multiple resistant Pseudomonas aeruginosa septicaemia treated with ciprofloxacin. J. R. Soc. Med.80(5), 316–317 (1987).
   PubMed Web of Science ®Google Scholar
• Brazas MD, Hancock RE. Ciprofloxacin induction of a susceptibility determinant in Pseudomonas aeruginosa. Antimicrob. Agents Chemother.49(8), 3222–3227 (2005).
   PubMed Web of Science ®Google Scholar
• Aaron SD, Ferris W, Ramotar K, Vandemheen K, Chan F, Saginur R. Single and combination antibiotic susceptibilities of planktonic, adherent, and biofilm-grown Pseudomonas aeruginosa isolates cultured from sputa of adults with cystic fibrosis. J. Clin. Microbiol.40(11), 4172–4179 (2002).
   PubMed Web of Science ®Google Scholar
• Smith AL, Fiel SB, Mayer-Hamblett N, Ramsey B, Burns JL. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest123(5), 1495–1502 (2003).
   PubMed Web of Science ®Google Scholar
• Fauvart M, De Groote VN, Michiels J. Role of persister cells in chronic infections: clinical relevance and perspectives on anti-persister therapies. J. Med. Microbiol.60(Pt 6), 699–709 (2011).
   PubMed Web of Science ®Google Scholar
• Bateman FL, Moss SM, Trott DJ, Shipstone MA. Biological efficacy and stability of diluted ticarcillin-clavulanic acid in the topical treatment of Pseudomonas aeruginosa infections. Vet. Dermatol. doi:10.1111/j.1365- 3164.2011.01018.x (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Theuretzbacher U. Future antibiotics scenarios: is the tide starting to turn? Int. J. Antimicrob. Agents34(1), 15–20 (2009).
   PubMed Web of Science ®Google Scholar
• Srinivas N, Jetter P, Ueberbacher BJ et al. Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa.Science327(5968), 1010–1013 (2010).
   PubMed Web of Science ®Google Scholar
• Lomovskaya O, Warren MS, Lee A et al. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob. Agents Chemother.45(1), 105–116 (2001).
   PubMed Web of Science ®Google Scholar
• Coban AY, Ekinci B, Durupinar B. A multidrug efflux pump inhibitor reduces fluoroquinolone resistance in Pseudomonas aeruginosa isolates. Chemotherapy50(1), 22–26 (2004).
   PubMed Web of Science ®Google Scholar
• Hocquet D, Roussel-Delvallez M, Cavallo JD, Plesiat P. MexAB-OprM- and MexXY-overproducing mutants are very prevalent among clinical strains of Pseudomonas aeruginosa with reduced susceptibility to ticarcillin. Antimicrob. Agents Chemother.51(4), 1582–1583 (2007).
   PubMed Web of Science ®Google Scholar
• Sanchez P, Linares JF, Ruiz-Diez B et al. Fitness of in vitro selected Pseudomonas aeruginosa nalB and nfxB multidrug resistant mutants. J. Antimicrob. Chemother.50(5), 657–664 (2002).
   PubMed Web of Science ®Google Scholar
• Michalopoulos A, Fotakis D, Virtzili S et al. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Respir. Med.102(3), 407–412 (2008).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Rafailidis PI. Re-emergence of colistin in today’s world of multidrug-resistant organisms: personal perspectives. Expert Opin. Investig. Drugs17(7), 973–981 (2008).
   PubMed Web of Science ®Google Scholar
• Costerton JW. Cystic fibrosis pathogenesis and the role of biofilms in persistent infection. Trends Microbiol.9(2), 50–52 (2001).
   PubMed Web of Science ®Google Scholar
• Singh PK, Schaefer AL, Parsek MR, Moninger TO, Welsh MJ, Greenberg EP. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature407(6805), 762–764 (2000).
   PubMed Web of Science ®Google Scholar
• Hentzer M, Teitzel GM, Balzer GJ et al. Alginate overproduction affects Pseudomonas aeruginosa biofilm structure and function. J. Bacteriol.183(18), 5395–5401 (2001).
   PubMed Web of Science ®Google Scholar
• Hoiby N, Ciofu O, Bjarnsholt T. Pseudomonas aeruginosa biofilms in cystic fibrosis. Future Microbiol.5(11), 1663–1674 (2011).
   Web of Science ®Google Scholar
• Borriello G, Werner E, Roe F, Kim AM, Ehrlich GD, Stewart PS. Oxygen limitation contributes to antibiotic tolerance of Pseudomonas aeruginosa in biofilms. Antimicrob. Agents Chemother.48(7), 2659–2664 (2004).
   PubMed Web of Science ®Google Scholar
• Werner E, Roe F, Bugnicourt A et al. Stratified growth in Pseudomonas aeruginosa biofilms. Appl. Environ. Microbiol.70(10), 6188–6196 (2004).
   PubMed Web of Science ®Google Scholar
• Moreau-Marquis S, Stanton BA, O’Toole GA. Pseudomonas aeruginosa biofilm formation in the cystic fibrosis airway. Pulm. Pharmacol. Ther.21(4), 595–599 (2008).
   PubMed Web of Science ®Google Scholar
• Whiteley M, Bangera MG, Bumgarner RE et al. Gene expression in Pseudomonas aeruginosa biofilms. Nature413(6858), 860–864 (2001).
   PubMed Web of Science ®Google Scholar
• Wagner VE, Gillis RJ, Iglewski BH. Transcriptome analysis of quorum-sensing regulation and virulence factor expression in Pseudomonas aeruginosa. Vaccine22(Suppl. 1), S15–S20 (2004).
   Web of Science ®Google Scholar
• Parsek MR, Singh PK. Bacterial biofilms: an emerging link to disease pathogenesis. Annu. Rev. Microbiol.57, 677–701 (2003).
   PubMed Web of Science ®Google Scholar
• Moskowitz SM, Foster JM, Emerson JC, Gibson RL, Burns JL. Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection. J. Antimicrob. Chemother.56(5), 879–886 (2005).
   PubMed Web of Science ®Google Scholar
• Moskowitz SM, Emerson JC, McNamara S et al. Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection. Pediatr. Pulmonol.46(2), 184–192 (2011).
   PubMed Web of Science ®Google Scholar
• Lewis K. Multidrug tolerance of biofilms and persister cells. Curr. Top. Microbiol. Immunol.322, 107–131 (2008).
   PubMed Web of Science ®Google Scholar
• Hoffmann N, Rasmussen TB, Jensen PO et al. Novel mouse model of chronic Pseudomonas aeruginosa lung infection mimicking cystic fibrosis. Infect. Immun.73(4), 2504–2514 (2005).
   PubMed Web of Science ®Google Scholar
• Nucleo E, Steffanoni L, Fugazza G et al. Growth in glucose-based medium and exposure to subinhibitory concentrations of imipenem induce biofilm formation in a multidrug-resistant clinical isolate of Acinetobacter baumannii. BMC Microbiol.9, 270 (2009).
   PubMed Web of Science ®Google Scholar
• Sriramulu DD, Lunsdorf H, Lam JS, Romling U. Microcolony formation: a novel biofilm model of Pseudomonas aeruginosa for the cystic fibrosis lung. J. Med. Microbiol.54(Pt 7), 667–676 (2005).
   PubMed Web of Science ®Google Scholar
• Ghani M, Soothill JS. Ceftazidime, gentamicin, and rifampicin, in combination, kill biofilms of mucoid Pseudomonas aeruginosa. Can. J. Microbiol.43(11), 999–1004 (1997).
   PubMed Web of Science ®Google Scholar
• Doring G, Conway SP, Heijerman HG et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur. Respir. J.16(4), 749–767 (2000).
   PubMed Web of Science ®Google Scholar
• Hoiby N, Ciofu O, Johansen HK et al. The clinical impact of bacterial biofilms. Int. J. Oral Sci.3(2), 55–65 (2011).
   PubMed Web of Science ®Google Scholar
• Frederiksen B, Pressler T, Hansen A, Koch C, Hoiby N. Effect of aerosolized rhDNase (Pulmozyme) on pulmonary colonization in patients with cystic fibrosis. Acta Paediatr.95(9), 1070–1074 (2006).
   PubMed Web of Science ®Google Scholar
• Hassett DJ, Korfhagen TR, Irvin RT et al.Pseudomonas aeruginosa biofilm infections in cystic fibrosis: insights into pathogenic processes and treatment strategies. Expert Opin. Ther. Targets14(2), 117–130 (2010).
   PubMed Web of Science ®Google Scholar
• Tamayo R, Pratt JT, Camilli A. Roles of cyclic diguanylate in the regulation of bacterial pathogenesis. Ann. Rev. Microbiol.61, 131–148 (2007).
   PubMed Web of Science ®Google Scholar
• Karatan E, Watnick P. Signals, regulatory networks, and materials that build and break bacterial biofilms. Microbiol. Mol. Biol. Rev.73(2), 310–347 (2009).
   PubMed Web of Science ®Google Scholar
• Tielker D, Hacker S, Loris R et al.Pseudomonas aeruginosa lectin LecB is located in the outer membrane and is involved in biofilm formation. Microbiology151(Pt 5), 1313–1323 (2005).
   PubMed Web of Science ®Google Scholar
• Diggle SP, Stacey RE, Dodd C, Camara M, Williams P, Winzer K. The galactophilic lectin, LecA, contributes to biofilm development in Pseudomonas aeruginosa. Environ. Microbiol.8(6), 1095–1104 (2006).
   PubMed Web of Science ®Google Scholar
• McIver K, Kessler E, Ohman DE. Substitution of active-site His-223 in Pseudomonas aeruginosa elastase and expression of the mutated lasB alleles in Escherichia coli show evidence for autoproteolytic processing of proelastase. J. Bacteriol.173(24), 7781–7789 (1991).
   PubMed Web of Science ®Google Scholar
• Johansson EM, Crusz SA, Kolomiets E et al. Inhibition and dispersion of Pseudomonas aeruginosa biofilms by glycopeptide dendrimers targeting the fucose-specific lectin LecB. Chem. Biol.15(12), 1249–1257 (2008).
   PubMedGoogle Scholar
• Hauber HP, Schulz M, Pforte A, Mack D, Zabel P, Schumacher U. Inhalation with fucose and galactose for treatment of Pseudomonas aeruginosa in cystic fibrosis patients. Int. J. Med. Sci.5(6), 371–376 (2008).
   PubMedGoogle Scholar
• von Bismarck P, Schneppenheim R, Schumacher U. Successful treatment of Pseudomonas aeruginosa respiratory tract infection with a sugar solution – a case report on a lectin based therapeutic principle. Klinische Padiatrie213(5), 285–287 (2001).
   PubMed Web of Science ®Google Scholar
• Mathee K, Ciofu O, Sternberg C et al. Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. Microbiology145(Pt 6), 1349–1357 (1999).
   PubMed Web of Science ®Google Scholar
• Boyd A, Chakrabarty AM. Pseudomonas aeruginosa biofilms: role of the alginate exopolysaccharide. J. Ind. Microbiol.15(3), 162–168 (1995).
   PubMedGoogle Scholar
• Ghafoor A, Hay ID, Rehm BH. Role of exopolysaccharides in Pseudomonas aeruginosa biofilm formation and architecture. Appl. Environ. Microbiol.77(15), 5238–5246 (2011).
   PubMed Web of Science ®Google Scholar
• Doggett RG, Harrison GM, Wallis ES. Comparison of some properties of Pseudomonas aeruginosa isolated from infections in persons with and without cystic fibrosis. J. Bacteriol.87, 427–431 (1964).
   PubMed Web of Science ®Google Scholar
• Cobb LM, Mychaleckyj JC, Wozniak DJ, Lopez-Boado YS. Pseudomonas aeruginosa flagellin and alginate elicit very distinct gene expression patterns in airway epithelial cells: implications for cystic fibrosis disease. J. Immunol.173(9), 5659–5670 (2004).
   PubMed Web of Science ®Google Scholar
• Simpson JA, Smith SE, Dean RT. Scavenging by alginate of free radicals released by macrophages. Free Radic. Biol. Med.6(4), 347–353 (1989).
   PubMed Web of Science ®Google Scholar
• Dibdin GH, Assinder SJ, Nichols WW, Lambert PA. Mathematical model of beta-lactam penetration into a biofilm of Pseudomonas aeruginosa while undergoing simultaneous inactivation by released beta-lactamases. J. Antimicrob. Chemother.38(5), 757–769 (1996).
   PubMed Web of Science ®Google Scholar
• Hatch RA, Schiller NL. Alginate lyase promotes diffusion of aminoglycosides through the extracellular polysaccharide of mucoid Pseudomonas aeruginosa. Antimicrob. Agents Chemother.42(4), 974–977 (1998).
   PubMed Web of Science ®Google Scholar
• Alkawash MA, Soothill JS, Schiller NL. Alginate lyase enhances antibiotic killing of mucoid Pseudomonas aeruginosa in biofilms. APMIS114(2), 131–138 (2006).
   PubMed Web of Science ®Google Scholar
• Alipour M, Suntres ZE, Omri A. Importance of DNase and alginate lyase for enhancing free and liposome encapsulated aminoglycoside activity against Pseudomonas aeruginosa. J. Antimicrob. Chemother.64(2), 317–325 (2009).
   PubMed Web of Science ®Google Scholar
• Bayer AS, Park S, Ramos MC, Nast CC, Eftekhar F, Schiller NL. Effects of alginase on the natural history and antibiotic therapy of experimental endocarditis caused by mucoid Pseudomonas aeruginosa. Infect. Immun.60(10), 3979–3985 (1992).
   PubMed Web of Science ®Google Scholar
• Lamppa JW, Ackerman ME, Lai JI, Scanlon TC, Griswold KE. Genetically engineered alginate lyase-PEG conjugates exhibit enhanced catalytic function and reduced immunoreactivity. PLoS ONE6(2), e17042 (2011).
   PubMed Web of Science ®Google Scholar
• Kulasakara H, Lee V, Brencic A et al. Analysis of Pseudomonas aeruginosa diguanylate cyclases and phosphodiesterases reveals a role for bis-(3´-5´)-cyclic-GMP in virulence. Proc. Natl Acad. Sci. USA103(8), 2839–2844 (2006).
   PubMed Web of Science ®Google Scholar
• Simm R, Morr M, Kader A, Nimtz M, Romling U. GGDEF and EAL domains inversely regulate cyclic di-GMP levels and transition from sessility to motility. Mol. Microbiol.53(4), 1123–1134 (2004).
   PubMed Web of Science ®Google Scholar
• Sudarsan N, Lee ER, Weinberg Z et al. Riboswitches in eubacteria sense the second messenger cyclic di-GMP. Science321(5887), 411–413 (2008).
   PubMed Web of Science ®Google Scholar
• Antoniani D, Bocci P, Maciag A, Raffaelli N, Landini P. Monitoring of diguanylate cyclase activity and of cyclic-di-GMP biosynthesis by whole-cell assays suitable for high-throughput screening of biofilm inhibitors. Appl. Microbiol. Biotechnol.85(4), 1095–1104 (2010).
   PubMed Web of Science ®Google Scholar
• Ueda A, Attila C, Whiteley M, Wood TK. Uracil influences quorum sensing and biofilm formation in Pseudomonas aeruginosa and fluorouracil is an antagonist. Microb. Biotechnol.2(1), 62–74 (2009).
   PubMed Web of Science ®Google Scholar
• Landini P, Antoniani D, Burgess JG, Nijland R. Molecular mechanisms of compounds affecting bacterial biofilm formation and dispersal. Appl. Microbiol. Biotechnol.86(3), 813–823 (2010).
   PubMed Web of Science ®Google Scholar
• Sauer K, Cullen MC, Rickard AH, Zeef LA, Davies DG, Gilbert P. Characterization of nutrient-induced dispersion in Pseudomonas aeruginosa PAO1 biofilm. J. Bacteriol.186(21), 7312–7326 (2004).
   PubMed Web of Science ®Google Scholar
• Gjermansen M, Ragas P, Sternberg C, Molin S, Tolker-Nielsen T. Characterization of starvation-induced dispersion in Pseudomonas putida biofilms. Environ. Microbiol.7(6), 894–906 (2005).
   PubMed Web of Science ®Google Scholar
• Thormann KM, Saville RM, Shukla S, Spormann AM. Induction of rapid detachment in Shewanella oneidensis MR-1 biofilms. J. Bacteriol.187(3), 1014–1021 (2005).
   PubMed Web of Science ®Google Scholar
• Barraud N, Hassett DJ, Hwang SH, Rice SA, Kjelleberg S, Webb JS. Involvement of nitric oxide in biofilm dispersal of Pseudomonas aeruginosa.J. Bacteriol.188(21), 7344–7353 (2006).
   PubMed Web of Science ®Google Scholar
• Barraud N, Schleheck D, Klebensberger J et al. Nitric oxide signaling in Pseudomonas aeruginosa biofilms mediates phosphodiesterase activity, decreased cyclic di-GMP levels, and enhanced dispersal. J. Bacteriol.191(23), 7333–7342 (2009).
   PubMed Web of Science ®Google Scholar
• Davies DG, Marques CN. A fatty acid messenger is responsible for inducing dispersion in microbial biofilms. J. Bacteriol.191(5), 1393–1403 (2009).
   PubMed Web of Science ®Google Scholar
• Webb JS, Lau M, Kjelleberg S. Bacteriophage and phenotypic variation in Pseudomonas aeruginosa biofilm development. J. Bacteriol.186(23), 8066–8073 (2004).
   PubMed Web of Science ®Google Scholar
• Rice SA, Tan CH, Mikkelsen PJ et al. The biofilm life cycle and virulence of Pseudomonas aeruginosa are dependent on a filamentous prophage. ISME J.3(3), 271–282 (2009).
   PubMed Web of Science ®Google Scholar
• Friedman A, Blecher K, Sanchez D et al. Susceptibility of Gram-positive and -negative bacteria to novel nitric oxide-releasing nanoparticle technology. Virulence2(3), 217–221 (2011).
   PubMed Web of Science ®Google Scholar
• Sintim HO, Smith JA, Wang J, Nakayama S, Yan L. Paradigm shift in discovering next-generation anti-infective agents: targeting quorum sensing, c-di-GMP signaling and biofilm formation in bacteria with small molecules. Future Med. Chem.2(6), 1005–1035 (2010).
   PubMed Web of Science ®Google Scholar
• Junker LM, Clardy J. High-throughput screens for small-molecule inhibitors of Pseudomonas aeruginosa biofilm development. Antimicrob. Agents Chemother.51(10), 3582–3590 (2007).
   PubMed Web of Science ®Google Scholar
• Wu H, Lee B, Yang L et al. Effects of ginseng on Pseudomonas aeruginosa motility and biofilm formation. FEMS Immunol. Med. Microbiol.62(1), 49–56 (2011).
   PubMed Web of Science ®Google Scholar
• Kostenko V, Lyczak J, Turner K, Martinuzzi RJ. Impact of silver-containing wound dressings on bacterial biofilm viability and susceptibility to antibiotics during prolonged treatment. Antimicrob. Agents Chemother.54(12), 5120–5131 (2010).
   PubMed Web of Science ®Google Scholar
• Bjarnsholt T, Kirketerp-Moller K, Kristiansen S et al. Silver against Pseudomonas aeruginosa biofilms. APMIS115(8), 921–928 (2007).
   PubMed Web of Science ®Google Scholar
• Kalishwaralal K, BarathManiKanth S, Pandian SR, Deepak V, Gurunathan S. Silver nanoparticles impede the biofilm formation by Pseudomonas aeruginosa and Staphylococcus epidermidis. Colloids Surf. B Biointerfaces79(2), 340–344 (2010).
   PubMed Web of Science ®Google Scholar
• Dean SN, Bishop BM, van Hoek ML. Susceptibility of Pseudomonas aeruginosa biofilm to alpha-helical peptides: D-enantiomer of LL-37. Front Microbiol.2, 128 (2011).
   PubMed Web of Science ®Google Scholar
• Eckert R. Road to clinical efficacy: challenges and novel strategies for antimicrobial peptide development. Future Microbiol.6, 635–651 (2011).
   PubMed Web of Science ®Google Scholar
• Lambert C, Fenton AK, Hobley L, Sockett RE. Predatory Bdellovibrio bacteria use gliding motility to scout for prey on surfaces. J. Bacteriol.193(12), 3139–3141 (2011).
   PubMed Web of Science ®Google Scholar
• Atterbury RJ, Hobley L, Till R et al. Studying the effects of orally administered Bdellovibrio on the wellbeing and Salmonella colonization of young chicks. Appl. Environ. Microbiol.77(16), 5794–5803 (2011).
   PubMed Web of Science ®Google Scholar
• Dashiff A, Junka RA, Libera M, Kadouri DE. Predation of human pathogens by the predatory bacteria Micavibrio aeruginosavorus and Bdellovibrio bacteriovorus. J. Appl. Microbiol.110(2), 431–444 (2011).
   PubMed Web of Science ®Google Scholar
• Passador L, Cook JM, Gambello MJ, Rust L, Iglewski BH. Expression of Pseudomonas aeruginosa virulence genes requires cell-to-cell communication. Science260(5111), 1127–1130 (1993).
   PubMed Web of Science ®Google Scholar
• Gambello MJ, Iglewski BH. Cloning and characterization of the Pseudomonas aeruginosa lasR gene, a transcriptional activator of elastase expression. J. Bacteriol.173(9), 3000–3009 (1991).
   PubMed Web of Science ®Google Scholar
• Girard G, Bloemberg GV. Central role of quorum sensing in regulating the production of pathogenicity factors in Pseudomonas aeruginosa. Future Microbiol.3(1), 97–106 (2008).
   PubMed Web of Science ®Google Scholar
• Gallagher LA, McKnight SL, Kuznetsova MS, Pesci EC, Manoil C. Functions required for extracellular quinolone signaling by Pseudomonas aeruginosa. J. Bacteriol.184(23), 6472–6480 (2002).
   PubMed Web of Science ®Google Scholar
• Winstanley C, Fothergill JL. The role of quorum sensing in chronic cystic fibrosis Pseudomonas aeruginosa infections. FEMS Microbiol. Lett.290(1), 1–9 (2009).
   PubMed Web of Science ®Google Scholar
• Bjarnsholt T, Jensen PO, Jakobsen TH et al. Quorum sensing and virulence of Pseudomonas aeruginosa during lung infection of cystic fibrosis patients. PLoS ONE5(4), e10115 (2010).
   PubMed Web of Science ®Google Scholar
• Kim EJ, Wang W, Deckwer WD, Zeng AP. Expression of the quorum-sensing regulatory protein LasR is strongly affected by iron and oxygen concentrations in cultures of Pseudomonas aeruginosa irrespective of cell density. Microbiology151(Pt 4), 1127–1138 (2005).
   PubMed Web of Science ®Google Scholar
• Schuster M, Lostroh CP, Ogi T, Greenberg EP. Identification, timing, and signal specificity of Pseudomonas aeruginosa quorum-controlled genes: a transcriptome analysis. J. Bacteriol.185(7), 2066–2079 (2003).
   PubMed Web of Science ®Google Scholar
• Wagner VE, Iglewski BH. P. aeruginosa biofilms in CF infection. Clin. Rev. Allergy Immunol.35(3), 124–134 (2008).
   PubMed Web of Science ®Google Scholar
• Cornelis P, Aendekerk S. A new regulator linking quorum sensing and iron uptake in Pseudomonas aeruginosa. Microbiology150(Pt 4), 752–756 (2004).
   PubMed Web of Science ®Google Scholar
• Davies DG, Parsek MR, Pearson JP, Iglewski BH, Costerton JW, Greenberg EP. The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science280(5361), 295–298 (1998).
   PubMed Web of Science ®Google Scholar
• Bjarnsholt T, Jensen PO, Rasmussen TB et al. Garlic blocks quorum sensing and promotes rapid clearing of pulmonary Pseudomonas aeruginosa infections. Microbiology151(Pt 12), 3873–3880 (2005).
   PubMed Web of Science ®Google Scholar
• Chapon-Herve V, Akrim M, Latifi A, Williams P, Lazdunski A, Bally M. Regulation of the xcp secretion pathway by multiple quorum-sensing modulons in Pseudomonas aeruginosa. Mol. Microbiol.24(6), 1169–1178 (1997).
   PubMed Web of Science ®Google Scholar
• Ochsner UA, Koch AK, Fiechter A, Reiser J. Isolation and characterization of a regulatory gene affecting rhamnolipid biosurfactant synthesis in Pseudomonas aeruginosa. J. Bacteriol.176(7), 2044–2054 (1994).
   PubMed Web of Science ®Google Scholar
• Pearson JP, Pesci EC, Iglewski BH. Roles of Pseudomonas aeruginosa las and rhl quorum-sensing systems in control of elastase and rhamnolipid biosynthesis genes. J. Bacteriol.179(18), 5756–5767 (1997).
   PubMed Web of Science ®Google Scholar
• Latifi A, Winson MK, Foglino M et al. Multiple homologues of LuxR and LuxI control expression of virulence determinants and secondary metabolites through quorum sensing in Pseudomonas aeruginosa PAO1. Mol. Microbiol.17(2), 333–343 (1995).
   PubMed Web of Science ®Google Scholar
• Latifi A, Foglino M, Tanaka K, Williams P, Lazdunski A. A hierarchical quorum-sensing cascade in Pseudomonas aeruginosa links the transcriptional activators LasR and RhIR (VsmR) to expression of the stationary-phase sigma factor RpoS. Mol. Microbiol.21(6), 1137–1146 (1996).
   PubMed Web of Science ®Google Scholar
• Juhas M, Wiehlmann L, Salunkhe P, Lauber J, Buer J, Tummler B. GeneChip expression analysis of the VqsR regulon of Pseudomonas aeruginosa TB. FEMS Microbiol. Lett.242(2), 287–295 (2005).
   PubMed Web of Science ®Google Scholar
• Kaufmann GF, Sartorio R, Lee SH et al. Revisiting quorum sensing: discovery of additional chemical and biological functions for 3-oxo-N-acylhomoserine lactones. Proc. Natl Acad. Sci. USA102(2), 309–314 (2005).
   PubMed Web of Science ®Google Scholar
• Venturi V. Regulation of quorum sensing in Pseudomonas. FEMS Microbiol. Rev.30(2), 274–291 (2006).
   PubMed Web of Science ®Google Scholar
• Novick RP, Geisinger E. Quorum sensing in staphylococci. Annu. Rev. Genet.42, 541–564 (2008).
   PubMed Web of Science ®Google Scholar
• Kong KF, Vuong C, Otto M. Staphylococcus quorum sensing in biofilm formation and infection. Int. J. Med. Microbiol.296(2–3), 133–139 (2006).
   PubMed Web of Science ®Google Scholar
• Bjarnsholt T, Jensen PO, Burmolle M et al.Pseudomonas aeruginosa tolerance to tobramycin, hydrogen peroxide and polymorphonuclear leukocytes is quorum-sensing dependent. Microbiology151(Pt 2), 373–383 (2005).
   PubMed Web of Science ®Google Scholar
• Wu H, Song Z, Hentzer M et al. Synthetic furanones inhibit quorum-sensing and enhance bacterial clearance in Pseudomonas aeruginosa lung infection in mice. J. Antimicrob. Chemother.53(6), 1054–1061 (2004).
   PubMed Web of Science ®Google Scholar
• Hoffmann N, Lee B, Hentzer M et al. Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. Antimicrob. Agents Chemother.51(10), 3677–3687 (2007).
   PubMed Web of Science ®Google Scholar
• Skindersoe ME, Alhede M, Phipps R et al. Effects of antibiotics on quorum sensing in Pseudomonas aeruginosa. Antimicrob. Agents Chemother.52(10), 3648–3663 (2008).
   PubMed Web of Science ®Google Scholar
• Moriarty TF, McElnay JC, Elborn JS, Tunney MM. Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection. Pediatr. Pulmonol.42(11), 1008–1017 (2007).
   PubMed Web of Science ®Google Scholar
• Smyth AR, Cifelli PM, Ortori CA et al. Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis – a pilot randomized controlled trial. Pediatr. Pulmonol.45(4), 356–362 (2010).
   PubMed Web of Science ®Google Scholar
• Beier D, Gross R. Regulation of bacterial virulence by two-component systems. Curr. Opin. Microbiol.9(2), 143–152 (2006).
   PubMed Web of Science ®Google Scholar
• Gooderham WJ, Hancock RE. Regulation of virulence and antibiotic resistance by two-component regulatory systems in Pseudomonas aeruginosa.FEMS Microbiol. Rev.33(2), 279–294 (2009).
   PubMed Web of Science ®Google Scholar
• Chauhan N, Calderone R. Two-component signal transduction proteins as potential drug targets in medically important fungi. Infect. Immun.76(11), 4795–4803 (2008).
   PubMed Web of Science ®Google Scholar
• Gotoh Y, Eguchi Y, Watanabe T, Okamoto S, Doi A, Utsumi R. Two-component signal transduction as potential drug targets in pathogenic bacteria. Curr. Opin. Microbiol.13(2), 232–239 (2010).
   PubMed Web of Science ®Google Scholar
• Lee VT, Smith RS, Tummler B, Lory S. Activities of Pseudomonas aeruginosa effectors secreted by the Type III secretion system in vitro and during infection. Infect. Immun.73(3), 1695–1705 (2005).
   PubMed Web of Science ®Google Scholar
• Goure J, Broz P, Attree O, Cornelis GR, Attree I. Protective anti-V antibodies inhibit Pseudomonas and Yersinia translocon assembly within host membranes. J. Infect. Dis.192(2), 218–225 (2005).
   PubMed Web of Science ®Google Scholar
• Frank DW, Vallis A, Wiener-Kronish JP et al. Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J. Infect. Dis.186(1), 64–73 (2002).
   PubMed Web of Science ®Google Scholar
• Meyer JM, Neely A, Stintzi A, Georges C, Holder IA. Pyoverdin is essential for virulence of Pseudomonas aeruginosa. Infect. Immun.64(2), 518–523 (1996).
   PubMed Web of Science ®Google Scholar
• Handfield M, Lehoux DE, Sanschagrin F, Mahan MJ, Woods DE, Levesque RC. In vivo-induced genes in Pseudomonas aeruginosa. Infect. Immun.68(4), 2359–2362 (2000).
   PubMed Web of Science ®Google Scholar
• Lamont IL, Beare PA, Ochsner U, Vasil AI, Vasil ML. Siderophore-mediated signaling regulates virulence factor production in Pseudomonas aeruginosa. Proc. Natl Acad. Sci. USA99(10), 7072–7077 (2002).
   PubMed Web of Science ®Google Scholar
• de Chial M, Ghysels B, Beatson SA et al. Identification of type II and type III pyoverdine receptors from Pseudomonas aeruginosa. Microbiology149(Pt 4), 821–831 (2003).
   PubMed Web of Science ®Google Scholar
• Halwani M, Yebio B, Suntres ZE, Alipour M, Azghani AO, Omri A. Co-encapsulation of gallium with gentamicin in liposomes enhances antimicrobial activity of gentamicin against Pseudomonas aeruginosa. J. Antimicrob. Chemother.62(6), 1291–1297 (2008).
   PubMed Web of Science ®Google Scholar
• Michel-Briand Y, Baysse C. The pyocins of Pseudomonas aeruginosa. Biochimie84(5–6), 499–510 (2002).
   PubMed Web of Science ®Google Scholar
• Filiatrault MJ, Munson RS Jr, Campagnari AA. Genetic analysis of a pyocin-resistant lipooligosaccharide (LOS) mutant of Haemophilus ducreyi: restoration of full-length LOS restores pyocin sensitivity. J. Bacteriol.183(19), 5756–5761 (2001).
   PubMed Web of Science ®Google Scholar
• Bakkal S, Robinson SM, Ordonez CL, Waltz DA, Riley MA. Role of bacteriocins in mediating interactions of bacterial isolates taken from cystic fibrosis patients. Microbiology156(Pt 7), 2058–2067 (2010).
   PubMed Web of Science ®Google Scholar
• Govan JR. In vivo significance of bacteriocins and bacteriocin receptors. Scand. J. Infect. Dis. Suppl.49, 31–37 (1986).
   PubMedGoogle Scholar
• Williams SR, Gebhart D, Martin DW, Scholl D. Retargeting R-type pyocins to generate novel bactericidal protein complexes. Appl. Environ. Microbiol.74(12), 3868–3876 (2008).
   PubMed Web of Science ®Google Scholar
• Scholl D, Martin DW Jr. Antibacterial efficacy of R-type pyocins towards Pseudomonas aeruginosa in a murine peritonitis model. Antimicrob. Agents Chemother.52(5), 1647–1652 (2008).
   PubMed Web of Science ®Google Scholar
• Line JE, Svetoch EA, Eruslanov BV et al. Isolation and purification of enterocin E-760 with broad antimicrobial activity against Gram-positive and Gram-negative bacteria. Antimicrob. Agents Chemother.52(3), 1094–1100 (2008).
   PubMed Web of Science ®Google Scholar
• Cherif A, Chehimi S, Limem F et al. Detection and characterization of the novel bacteriocin entomocin 9, and safety evaluation of its producer, Bacillus thuringiensis ssp. entomocidus HD9. J. Appl. Microbiol.95(5), 990–1000 (2003).
   PubMed Web of Science ®Google Scholar
• Ling H, Saeidi N, Rasouliha BH, Chang MW. A predicted S-type pyocin shows a bactericidal activity against clinical Pseudomonas aeruginosa isolates through membrane damage. FEBS Lett.584(15), 3354–3358 (2010).
   PubMed Web of Science ®Google Scholar
• Montalban-Lopez M, Sanchez-Hidalgo M, Valdivia E, Martinez-Bueno M, Maqueda M. Are bacteriocins underexploited? Novel applications for old antimicrobials. Curr. Pharm. Biotechnol.12(8), 1205–1220 (2011).
   PubMed Web of Science ®Google Scholar
• Svetoch EA, Stern NJ. Bacteriocins to control Campylobacter spp. in poultry – a review. Poult. Sci.89(8), 1763–1768 (2010).
   PubMed Web of Science ®Google Scholar
• Sang Y, Blecha F. Antimicrobial peptides and bacteriocins: alternatives to traditional antibiotics. Anim. Health Res. Rev.9(2), 227–235 (2008).
   PubMedGoogle Scholar
• Allaker RP, Douglas CW. Novel anti-microbial therapies for dental plaque-related diseases. Int. J. Antimicrob. Agents33(1), 8–13 (2009).
   PubMed Web of Science ®Google Scholar
• Corr SC, Hill C, Gahan CG. Understanding the mechanisms by which probiotics inhibit gastrointestinal pathogens. Adv. Food Nutr. Res.56, 1–15 (2009).
   PubMedGoogle Scholar
• Denayer S, Matthijs S, Cornelis P. Pyocin S2 (Sa) kills Pseudomonas aeruginosa strains via the FpvA type I ferripyoverdine receptor. J. Bacteriol.189(21), 7663–7668 (2007).
   PubMed Web of Science ®Google Scholar
• Hendrix RW, Smith MC, Burns RN, Ford ME, Hatfull GF. Evolutionary relationships among diverse bacteriophages and prophages: all the world’s a phage. Proc. Natl Acad. Sci. USA96(5), 2192–2197 (1999).
   PubMed Web of Science ®Google Scholar
• Summers WC. Bacteriophage therapy. Annu. Rev. Microbiol.55, 437–451 (2001).
   PubMed Web of Science ®Google Scholar
• Levin BR, Bull JJ. Population and evolutionary dynamics of phage therapy. Nat. Rev. Microbiol.2(2), 166–173 (2004).
   PubMed Web of Science ®Google Scholar
• Stone R. Bacteriophage therapy. Stalin’s forgotten cure. Science298(5594), 728–731 (2002).
   PubMed Web of Science ®Google Scholar
• Cooper CJ, Denyer SP, Maillard JY. Rapid and quantitative automated measurement of bacteriophage activity against cystic fibrosis isolates of Pseudomonas aeruginosa. J. Appl. Microbiol.110(3), 631–640 (2011).
   PubMed Web of Science ®Google Scholar
• Azeredo J, Sutherland IW. The use of phages for the removal of infectious biofilms. Curr. Pharm. Biotechnol.9(4), 261–266 (2008).
   PubMed Web of Science ®Google Scholar
• Harper DR, Enright MC. Bacteriophages for the treatment of Pseudomonas aeruginosa infections. J. Appl. Microbiol.111(1), 1–7 (2011).
   PubMed Web of Science ®Google Scholar
• Hanlon GW, Denyer SP, Olliff CJ, Ibrahim LJ. Reduction in exopolysaccharide viscosity as an aid to bacteriophage penetration through Pseudomonas aeruginosa biofilms. Appl. Environ. Microbiol.67(6), 2746–2753 (2001).
   PubMed Web of Science ®Google Scholar
• Bartell PF, Orr TE, Lam GK. Polysaccharide depolymerase associated with bacteriophage infection. J. Bacteriol.92(1), 56–62 (1966).
   PubMed Web of Science ®Google Scholar
• Reese JF, Dimitracopoulos G, Bartell PF. Factors influencing the adsorption of bacteriophage 2 to cells of Pseudomonas aeruginosa. J. Virol.13(1), 22–27 (1974).
   PubMed Web of Science ®Google Scholar
• Verma V, Harjai K, Chhibber S. Structural changes induced by a lytic bacteriophage make ciprofloxacin effective against older biofilm of Klebsiella pneumoniae. Biofouling26(6), 729–737 (2010).
   PubMed Web of Science ®Google Scholar
• Fu W, Forster T, Mayer O, Curtin JJ, Lehman SM, Donlan RM. Bacteriophage cocktail for the prevention of biofilm formation by Pseudomonas aeruginosa on catheters in an in vitro model system. Antimicrob. Agents Chemother.54(1), 397–404 (2010).
   PubMed Web of Science ®Google Scholar
• Garbe J, Wesche A, Bunk B et al. Characterization of JG024, a Pseudomonas aeruginosa PB1-like broad host range phage under simulated infection conditions. BMC Microbiol.10, 301 (2010).
   PubMed Web of Science ®Google Scholar
• Heo YJ, Lee YR, Jung HH, Lee J, Ko G, Cho YH. Antibacterial efficacy of phages against Pseudomonas aeruginosa infections in mice and Drosophila melanogaster. Antimicrob. Agents Chemother.53(6), 2469–2474 (2009).
   PubMed Web of Science ®Google Scholar
• McVay CS, Velasquez M, Fralick JA. Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrob. Agents Chemother.51(6), 1934–1938 (2007).
   PubMed Web of Science ®Google Scholar
• Debarbieux L, Leduc D, Maura D et al. Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J. Infect. Dis.201(7), 1096–1104 (2010).
   PubMed Web of Science ®Google Scholar
• Morello E, Saussereau E, Maura D, Huerre M, Touqui L, Debarbieux L. Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: first steps towards treatment and prevention. PLoS ONE6(2), e16963 (2011).
   PubMed Web of Science ®Google Scholar
• Hawkins C, Harper D, Burch D, Anggard E, Soothill J. Topical treatment of Pseudomonas aeruginosa otitis of dogs with a bacteriophage mixture: a before/after clinical trial. Vet. Microbiol.146(3–4), 309–313 (2010).
   PubMed Web of Science ®Google Scholar
• Wright A, Hawkins CH, Anggard EE, Harper DR. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin. Otolaryngol.34(4), 349–357 (2009).
   PubMed Web of Science ®Google Scholar
• Merabishvili M, Pirnay JP, Verbeken G et al. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS ONE4(3), e4944 (2009).
   PubMed Web of Science ®Google Scholar
• Golshahi L, Lynch KH, Dennis JJ, Finlay WH. In vitro lung delivery of bacteriophages KS4-M and PhiKZ using dry powder inhalers for treatment of Burkholderia cepacia complex and Pseudomonas aeruginosa infections in cystic fibrosis. J. Appl. Microbiol.110(1), 106–117 (2011).
   PubMed Web of Science ®Google Scholar
• Verbeken G, De Vos D, Vaneechoutte M, Merabishvili M, Zizi M, Pirnay JP. European regulatory conundrum of phage therapy. Future Microbiol.2(5), 485–491 (2007).
   PubMed Web of Science ®Google Scholar
• Lu TK, Collins JJ. Dispersing biofilms with engineered enzymatic bacteriophage. Proc. Natl Acad. Sci. USA104(27), 11197–11202 (2007).
   PubMed Web of Science ®Google Scholar
• Lu TK, Collins JJ. Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proc. Natl Acad. Sci. USA106(12), 4629–4634 (2009).
   PubMed Web of Science ®Google Scholar
• Hagens S, Habel A, von Ahsen U, von Gabain A, Blasi U. Therapy of experimental Pseudomonas infections with a nonreplicating genetically modified phage. Antimicrob. Agents Chemother.48(10), 3817–3822 (2004).
   PubMed Web of Science ®Google Scholar
• Wang Y, Lu C. [Bacteriophage lysins: progress and perspective – a review]. Wei Sheng Wu Xue Bao49(10), 1277–1281 (2009).
   PubMedGoogle Scholar
• Borysowski J, Weber-Dabrowska B, Gorski A. Bacteriophage endolysins as a novel class of antibacterial agents. Exp. Biol. Med. (Maywood)231(4), 366–377 (2006).
   PubMed Web of Science ®Google Scholar
• Nelson D, Loomis L, Fischetti VA. Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc. Natl Acad. Sci. USA98(7), 4107–4112 (2001).
   PubMed Web of Science ®Google Scholar
• Briers Y, Walmagh M, Lavigne R. Use of bacteriophage endolysin EL188 and outer membrane permeabilizers against Pseudomonas aeruginosa. J. Appl. Microbiol.110(3), 778–785 (2011).
   PubMed Web of Science ®Google Scholar
• Paradis-Bleau C, Cloutier I, Lemieux L et al. Peptidoglycan lytic activity of the Pseudomonas aeruginosa phage phiKZ gp144 lytic transglycosylase. FEMS Microbiol. Lett.266(2), 201–209 (2007).
   PubMed Web of Science ®Google Scholar
• Rashel M, Uchiyama J, Ujihara T et al. Efficient elimination of multidrug-resistant Staphylococcus aureus by cloned lysin derived from bacteriophage phi MR11. J. Infect. Dis.196(8), 1237–1247 (2007).
   PubMed Web of Science ®Google Scholar
• Fischetti VA. Bacteriophage lysins as effective antibacterials. Curr. Opin. Microbiol.11(5), 393–400 (2008).
   PubMed Web of Science ®Google Scholar
• Doring G, Pier GB. Vaccines and immunotherapy against Pseudomonas aeruginosa. Vaccine26(8), 1011–1024 (2008).
   PubMed Web of Science ®Google Scholar
• Pennington JE, Reynolds HY, Wood RE, Robinson RA, Levine AS. Use of a Pseudomonas aeruginosa vaccine in pateints with acute leukemia and cystic fibrosis. Am. J. Med.58(5), 629–636 (1975).
   PubMed Web of Science ®Google Scholar
• Cryz SJ Jr, Furer E, Que JU, Sadoff JC, Brenner M, Schaad UB. Clinical evaluation of an octavalent Pseudomonas aeruginosa conjugate vaccine in plasma donors and in bone marrow transplant and cystic fibrosis patients. Antibiot. Chemother.44, 157–162 (1991).
   PubMedGoogle Scholar
• Lang AB, Rudeberg A, Schoni MH, Que JU, Furer E, Schaad UB. Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection. Pediatr. Infect. Dis. J.23(6), 504–510 (2004).
   PubMed Web of Science ®Google Scholar
• Doring G, Meisner C, Stern M. A double-blind randomized placebo-controlled Phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proc. Natl Acad. Sci. USA104(26), 11020–11025 (2007).
   PubMed Web of Science ®Google Scholar
• Palliyil S, Broadbent ID. Novel immunotherapeutic approaches to the treatment of infections caused by Gram-negative bacteria. Curr. Opin. Pharmacol.9(5), 566–570 (2009).
   PubMed Web of Science ®Google Scholar
• Donta ST, Peduzzi P, Cross AS et al. Immunoprophylaxis against Klebsiella and Pseudomonas aeruginosa infections. The Federal Hyperimmune Immunoglobulin Trial Study Group. J. Infect. Dis.174(3), 537–543 (1996).
   PubMed Web of Science ®Google Scholar
• Baer M, Sawa T, Flynn P et al. An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity. Infect. Immun.77(3), 1083–1090 (2009).
   PubMed Web of Science ®Google Scholar
• Imamura Y, Yanagihara K, Fukuda Y et al. Effect of anti-PcrV antibody in a murine chronic airway Pseudomonas aeruginosa infection model. Eur. Respir. J.29(5), 965–968 (2007).
   PubMed Web of Science ®Google Scholar
• Holder IA, Neely AN, Frank DW. PcrV immunization enhances survival of burned Pseudomonas aeruginosa-infected mice. Infect. Immun.69(9), 5908–5910 (2001).
   PubMed Web of Science ®Google Scholar
• Faezi S, Sattari M, Mahdavi M, Roudkenar MH. Passive immunisation against Pseudomonas aeruginosa recombinant flagellin in an experimental model of burn wound sepsis. Burns37(5), 864–871 (2011).
   Google Scholar
• Moskwa P, Lorentzen D, Excoffon KJ et al. A novel host defense system of airways is defective in cystic fibrosis. Am. J. Respir. Crit. Care Med.175(2), 174–183 (2007).
   PubMed Web of Science ®Google Scholar
• Woodford N, Wareham DW. Tackling antibiotic resistance: a dose of common antisense? J. Antimicrob. Chemother.63(2), 225–229 (2009).
   PubMed Web of Science ®Google Scholar
• Hong-Geller E, Micheva-Viteva SN. Functional gene discovery using RNA interference-based genomic screens to combat pathogen infection. Curr. Drug Discov. Technol.7(2), 86–94 (2010).
   PubMedGoogle Scholar
• Bai H, Xue X, Hou Z, Zhou Y, Meng J, Luo X. Antisense antibiotics: a brief review of novel target discovery and delivery. Curr. Drug Discov. Technol.7(2), 76–85 (2010).
   PubMedGoogle Scholar
• Metzker ML. Sequencing technologies – the next generation. Nat. Rev. Genet.11(1), 31–46 (2010).
   PubMed Web of Science ®Google Scholar
• Gross H. Genomic mining – a concept for the discovery of new bioactive natural products. Curr. Opin. Drug Discov. Devel.12(2), 207–219 (2009).
   PubMed Web of Science ®Google Scholar
• Eberl L, Riedel K. Mining quorum sensing regulated proteins – role of bacterial cell-to-cell communication in global gene regulation as assessed by proteomics. Proteomics11(15), 3070–3085 (2011).
   PubMed Web of Science ®Google Scholar
• Davies J. How to discover new antibiotics: harvesting the parvome. Curr. Opin. Chem. Biol.15(1), 5–10 (2010).
   PubMed Web of Science ®Google Scholar
• Yacoby I, Benhar I. Targeted anti bacterial therapy. Infect. Disord. Drug Targets7(3), 221–229 (2007).
   PubMedGoogle Scholar
• Winsor GL, Van Rossum T, Lo R et al. Pseudomonas Genome Database: facilitating user-friendly, comprehensive comparisons of microbial genomes. Nucleic Acids Res.37(Database issue), D483–D488 (2009).
   PubMed Web of Science ®Google Scholar
• Cheng K, Smyth RL, Govan JR et al. Spread of β-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet348(9028), 639–642 (1996).
   PubMed Web of Science ®Google Scholar
• Anthony M, Rose B, Pegler MB et al. Genetic analysis of Pseudomonas aeruginosa isolates from the sputa of Australian adult cystic fibrosis patients. J. Clin. Microbiol.40(8), 2772–2778 (2002).
   PubMed Web of Science ®Google Scholar
• O’Carroll MR, Syrmis MW, Wainwright CE et al. Clonal strains of Pseudomonas aeruginosa in paediatric and adult cystic fibrosis units. Eur. Respir. J.24(1), 101–106 (2004).
   PubMed Web of Science ®Google Scholar
• Scott FW, Pitt TL. Identification and characterization of transmissible Pseudomonas aeruginosa strains in cystic fibrosis patients in England and Wales. J. Med. Microbiol.53(Pt 7), 609–615 (2004).
   PubMed Web of Science ®Google Scholar
• Jones AM, Govan JR, Doherty CJ et al. Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic. Lancet358(9281), 557–558 (2001).
   PubMed Web of Science ®Google Scholar
• Winstanley C, Langille MG, Fothergill JL et al. Newly introduced genomic prophage islands are critical determinants of in vivo competitiveness in the Liverpool Epidemic Strain of Pseudomonas aeruginosa. Genome Res.19(1), 12–23 (2009).
   PubMed Web of Science ®Google Scholar
• Parsons YN, Panagea S, Smart CH, Walshaw MJ, Hart CA, Winstanley C. Use of subtractive hybridization to identify a diagnostic probe for a cystic fibrosis epidemic strain of Pseudomonas aeruginosa. J. Clin. Microbiol.40(12), 4607–4611 (2002).
   PubMed Web of Science ®Google Scholar
• Fothergill JL, Mowat E, Ledson MJ, Walshaw MJ, Winstanley C. Fluctuations in phenotypes and genotypes within populations of Pseudomonas aeruginosa in the cystic fibrosis lung during pulmonary exacerbations. J. Med. Microbiol.59(Pt 4), 472–481 (2010).
   PubMed Web of Science ®Google Scholar
• Mowat E, Paterson S, Fothergill JL et al.Pseudomonas aeruginosa population diversity and turnover in cystic fibrosis chronic infections. Am. J. Respir. Crit. Care Med.183, 1674–1679 (2011).
   PubMed Web of Science ®Google Scholar
• Armougom F, Bittar F, Stremler N et al. Microbial diversity in the sputum of a cystic fibrosis patient studied with 16S rDNA pyrosequencing. Eur. J. Clin. Microbiol. Infect. Dis.28(9), 1151–1154 (2009).
   PubMed Web of Science ®Google Scholar
• Caporaso JG, Lauber CL, Costello EK et al. Moving pictures of the human microbiome. Genome Biol.12(5), R50 (2011).
   PubMed Web of Science ®Google Scholar
• Tunney MM, Field TR, Moriarty TF et al. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am. J. Respir. Crit. Care Med.177(9), 995–1001 (2008).
   PubMed Web of Science ®Google Scholar
• Cox MJ, Allgaier M, Taylor B et al. Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients. PLoS ONE5(6), e11044 (2011).
   Google Scholar
• Zemanick ET, Sagel SD, Harris JK. The airway microbiome in cystic fibrosis and implications for treatment. Curr. Opin. Pediatr.23(3), 319–324 (2011).
   PubMed Web of Science ®Google Scholar
• Friswell M, Campbell B, Rhodes J. The role of bacteria in the pathogenesis of inflammatory bowel disease. Gut Liver4(3), 295–306 (2010).
   PubMed Web of Science ®Google Scholar